Tag: disease-modifying therapy
-
The neurodegeneration disease-modifying-therapy landscape — amyloid removal is now unambiguous, but the small, contested clinical effect is the real bottleneck
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. Every effect size, reduction figure and surrogate result is attributed to the sponsoring trial or company; some sponsor-funded trials are noted inline. Surrogate endpoints (amyloid PET, plasma neurofilament) are kept…
Uthando Nethemba 